{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T05:43:41Z","timestamp":1650692621697},"reference-count":7,"publisher":"Japanese Urological Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2021,4,20]]},"DOI":"10.5980\/jpnjurol.112.105","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T22:13:22Z","timestamp":1650406402000},"page":"105-108","source":"Crossref","is-referenced-by-count":0,"title":["A CASE OF UNRESECTABLE METASTATIC RENAL CARCINOMA SUCCESSFULLY TREATED BY COMBINED MODALITY THERAPY WITH NIVOLUMAB AND SURGERY"],"prefix":"10.5980","volume":"112","author":[{"given":"Naomi","family":"Ohmori","sequence":"first","affiliation":[{"name":"Mimihara General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Oki","sequence":"additional","affiliation":[{"name":"Mimihara General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Tahara","sequence":"additional","affiliation":[{"name":"Mimihara General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M and Uemura H: Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III checkMate025 Study. Jpn J Clin Oncol, 49(6), 506-514, 2019.","DOI":"10.1093\/jjco\/hyz026"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) \u85e4\u672c \u6804, \u85e4\u7530 \u6566, \u6e4a \u6d69\u4e00, \u98ef\u5cf6 \u7f8e\u7802: \u30cb\u30dc\u30eb\u30de\u30d63\u56de\u6295\u4e0e\u306e\u307f\u3067\u5b8c\u5168\u594f\u52b9\u3068\u306a\u3063\u305f\u80ba\u6241\u5e73\u4e0a\u76ae\u764c\u306e1\u4f8b. \u80ba\u764c, 58(4), 292-297, 2018.","DOI":"10.2482\/haigan.58.292"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sponghini A, Patrucco F, Giorgione R, Farinelli P, Zottarelli F, Rondonotti D and Savoia P: Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient. Anticancer Drugs, 28(7), 808-810, 2017.","DOI":"10.1097\/CAD.0000000000000515"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lheure C, Hoffmann C, Kramkimel N, Plee J, Franck N, Vanhaecke C, Goldman-L\u00e9vy G, Bataillon G, Damotte D, Dupin N, Aractingi S, Grange F and Gu\u00e9gan S: Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1. Acta Derm Venereol, 99(1), 107-108, 2019.","DOI":"10.2340\/00015555-3028"},{"key":"5","unstructured":"5) \u585a\u539f \u8302\u5927, \u6c38\u51a8 \u88d5\u5b50, \u5927\u576a \u667a\u5fd7, \u9577\u8c37\u5ddd \u4fee\u4e8c: Nivolumab\u5358\u56de\u6295\u4e0e\u5f8c\u306b\u3066\u8ee2\u79fb\u5de3\u304c\u8457\u660e\u7e2e\u5c0f\u3057\u539f\u767a\u5de3\u5207\u9664\u304c\u53ef\u80fd\u3068\u306a\u3063\u305f\u814e\u7d30\u80de\u764c\u306e\u4e00\u4f8b. \u65e5\u6ccc\u4f1a\u8a8c, 110(1), 32-35, 2019."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Vgelzang JN, McFaelane JJ, Kochenderfer DM, Molina MA, Arrowsmith E, Bauer MT, Hauke JR, Jain R, Somer GB, Lam TE, Doshi KG, Gunuganti V, Zhang J, Zhao H, Johansen J and Tykodi SS: Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb\/IV CheckMate 374 study. J Clin Oncol, 37(7), 562, 2019.","DOI":"10.1200\/JCO.2019.37.7_suppl.562"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Giorgi DU, Scagliarini S, Basso U, Galli L, Mosillo C, Caserta C, Rossetti S, Guina A, Bearz A, Buti S, Re LG, Valcamonico F, Hamzaj A, Cognetti F, Rastelli F, Fornarini G, Porta C, Bene DG, Turci D and Procopio G: Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP). J Clin Oncol, 35(15), 4577, 2017.","DOI":"10.1200\/JCO.2017.35.15_suppl.4577"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/112\/2\/112_105\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T05:15:42Z","timestamp":1650690942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/112\/2\/112_105\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.112.105","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}